BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32133282)

  • 41. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study.
    Deng K; Wang L; Liu Y; Li X; Hou Q; Cao M; Ng NN; Wang H; Chen H; Yeom KW; Zhao M; Wu N; Gao P; Shi J; Liu Z; Li W; Tian J; Song J
    EClinicalMedicine; 2022 Sep; 51():101541. PubMed ID: 35813093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer.
    Wu J; Zhou Y; Xu C; Yang C; Liu B; Zhao L; Song J; Wang W; Yang Y; Liu N
    BMC Cancer; 2024 Feb; 24(1):170. PubMed ID: 38310283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI.
    Tang X; Li Y; Shen LT; Yan WF; Qian WL; Yang ZG
    Acad Radiol; 2023 Nov; 30(11):2574-2587. PubMed ID: 36941156
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Semiquantitative parameters of
    Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
    Shinde R; Cao X; Kothari S
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
    Xing P; Zhao Q; Zhang L; Wang H; Huang D; Hu P; Sun Y; Shi Y
    BMC Med; 2022 Nov; 20(1):453. PubMed ID: 36424628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.
    Kim KH; Kim J; Park H; Kim H; Lee SH; Sohn I; Lee HY; Park WY
    Thorac Cancer; 2020 Sep; 11(9):2542-2551. PubMed ID: 32700470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients.
    Britschgi C; Addeo A; Rechsteiner M; Delaloye R; Früh M; Metro G; Banini M; Gautschi O; Rothschild SI; Wild PJ; Banna GL; Curioni-Fontecedro A
    Front Oncol; 2020; 10():1299. PubMed ID: 32974130
    [No Abstract]   [Full Text] [Related]  

  • 50. Homology-based radiomic features for prediction of the prognosis of lung cancer based on CT-based radiomics.
    Kadoya N; Tanaka S; Kajikawa T; Tanabe S; Abe K; Nakajima Y; Yamamoto T; Takahashi N; Takeda K; Dobashi S; Takeda K; Nakane K; Jingu K
    Med Phys; 2020 Jun; 47(5):2197-2205. PubMed ID: 32096876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.
    Zhu X; Dong D; Chen Z; Fang M; Zhang L; Song J; Yu D; Zang Y; Liu Z; Shi J; Tian J
    Eur Radiol; 2018 Jul; 28(7):2772-2778. PubMed ID: 29450713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CT radiomics-based prediction of anaplastic lymphoma kinase and epidermal growth factor receptor mutations in lung adenocarcinoma.
    Choe J; Lee SM; Kim W; Do KH; Kim S; Choi S; Seo JB
    Eur J Radiol; 2021 Jun; 139():109710. PubMed ID: 33862316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel radiomic signature as a prognostic biomarker for locally advanced rectal cancer.
    Meng Y; Zhang Y; Dong D; Li C; Liang X; Zhang C; Wan L; Zhao X; Xu K; Zhou C; Tian J; Zhang H
    J Magn Reson Imaging; 2018 Feb; ():. PubMed ID: 29437271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting Chemo-Radiotherapy Sensitivity With Concordant Survival Benefit in Non-Small Cell Lung Cancer
    Liu Y; Qi H; Wang C; Deng J; Tan Y; Lin L; Cui Z; Li J; Qi L
    Front Oncol; 2022; 12():832343. PubMed ID: 35814422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.
    Yang L; Xu P; Li M; Wang M; Peng M; Zhang Y; Wu T; Chu W; Wang K; Meng H; Zhang L
    Front Oncol; 2022; 12():894323. PubMed ID: 35800046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by
    Li J; Ge S; Sang S; Hu C; Deng S
    Front Oncol; 2021; 11():789014. PubMed ID: 34976829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images.
    van Timmeren JE; Leijenaar RTH; van Elmpt W; Reymen B; Oberije C; Monshouwer R; Bussink J; Brink C; Hansen O; Lambin P
    Radiother Oncol; 2017 Jun; 123(3):363-369. PubMed ID: 28506693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of interim
    Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
    Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients.
    Song Z; Liu T; Shi L; Yu Z; Shen Q; Xu M; Huang Z; Cai Z; Wang W; Xu C; Sun J; Chen M
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):361-371. PubMed ID: 32794105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.